Onconova therapeutics, inc. (ONTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenue

2,183

1,228

787

5,546

11,456

800

4,753

46,190

1,487

Operating expenses:
General and administrative

8,345

7,586

7,405

9,178

9,533

15,119

16,793

15,707

6,436

Research and development

15,537

16,924

19,119

20,071

25,895

49,425

50,182

52,762

22,624

Total operating expenses

23,882

24,510

26,524

29,249

35,428

64,544

66,975

68,469

29,060

Loss from operations

-21,699

-23,282

-25,737

-23,703

-23,972

-63,744

-62,222

-22,279

-27,573

Change in fair value of warrant liability

-63

-1,597

-1,628

-3,988

-

-20

-42

-367

-1,287

Interest expense

-

-

-

-

-

-

4

8,608

19

Other income, net

143

1,151

30

62

-35

-52

63

608

11

Net loss before income taxes

-21,493

-20,534

-24,079

-19,653

-24,007

-63,776

-62,121

-29,912

-26,294

Income tax expense (benefit)

10

-124

13

14

16

19

435

-

-

Net loss

-21,503

-20,410

-24,092

-19,667

-24,023

-63,795

-62,556

-29,912

-26,294

Net gain attributable to non-controlling interest

-

163

-

-

-44

-113

-13

-

-

Net loss attributable to Onconova Therapeutics, Inc.

-21,503

-20,573

-24,092

-19,667

-23,979

-63,682

-62,543

-29,912

-26,294

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

2,320

3,953

4,020

Net loss applicable to common stockholders

-

-

-

-

-

-

-64,863

-33,865

-30,314

Net loss per share, basic and diluted (in dollars per share)

-1.49

-4.99

-40.15

-4.44

-10.54

-2.94

-6.12

-15.35

-14.18

Basic and diluted weighted average shares outstanding (in shares)

14,384

4,124

600

4,426

2,273

21,653

10,594

2,206

2,137